John Kao Sells 180,000 Shares of Alignment Healthcare (NASDAQ:ALHC) Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) CEO John Kao sold 180,000 shares of Alignment Healthcare stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $20.49, for a total transaction of $3,688,200.00. Following the completion of the sale, the chief executive officer directly owned 2,652,641 shares in the company, valued at approximately $54,352,614.09. This represents a 6.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Alignment Healthcare Price Performance

Alignment Healthcare stock opened at $20.39 on Thursday. Alignment Healthcare, Inc. has a one year low of $11.63 and a one year high of $23.87. The firm has a market capitalization of $4.08 billion, a P/E ratio of -169.92, a PEG ratio of 5.26 and a beta of 1.16. The company has a debt-to-equity ratio of 1.99, a current ratio of 1.61 and a quick ratio of 1.61. The business has a fifty day moving average price of $20.88 and a 200-day moving average price of $17.98.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Teacher Retirement System of Texas lifted its holdings in shares of Alignment Healthcare by 85.8% during the 3rd quarter. Teacher Retirement System of Texas now owns 102,827 shares of the company’s stock valued at $1,794,000 after acquiring an additional 47,472 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in Alignment Healthcare in the 3rd quarter worth approximately $3,499,000. Inspire Investing LLC acquired a new stake in Alignment Healthcare in the third quarter valued at approximately $1,129,000. Ameritas Investment Partners Inc. raised its stake in shares of Alignment Healthcare by 32.9% during the second quarter. Ameritas Investment Partners Inc. now owns 13,031 shares of the company’s stock valued at $182,000 after purchasing an additional 3,225 shares during the period. Finally, Schroder Investment Management Group lifted its position in shares of Alignment Healthcare by 28.7% during the second quarter. Schroder Investment Management Group now owns 248,163 shares of the company’s stock worth $3,437,000 after purchasing an additional 55,314 shares in the last quarter. 86.19% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ALHC. Piper Sandler raised their price objective on shares of Alignment Healthcare from $20.00 to $30.00 and gave the stock an “overweight” rating in a report on Tuesday, January 6th. Robert W. Baird set a $28.00 target price on shares of Alignment Healthcare in a research note on Friday, January 30th. Wall Street Zen raised Alignment Healthcare from a “hold” rating to a “buy” rating in a research report on Saturday, February 7th. JPMorgan Chase & Co. lifted their target price on shares of Alignment Healthcare from $23.00 to $26.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Finally, Barclays increased their price objective on shares of Alignment Healthcare from $13.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.32.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.